Oryzon Genomics is a biopharmaceutical company developing epigenetics-based therapeutics for patients with cancer and CNS disorders. Oryzon is able to identify and validate biomarkers and therapeutic targets through its epigenetic platform and turn them into advanced and personalized therapies. Oryzon Genomics has a growing portfolio, with two compounds in Phase II clinical trials: iadademstat (aka ORY-1001), a potent and selective LSD1 inhibitor for oncology, and vafidemstat (aka ORY-2001), a CNS optimized LSD1 inhibitor for the treatment of neurological diseases. The portfolio includes ORY-3001, a selective LSD1 inhibitor in preclinical development for the treatment of non-oncological diseases.

University Hospital Freiburg is a healthcare organization that offers research, education, clinical practice, and treatment programs. Freiburg University Medical Center ensures the possible care for their patients by bundling their knowledge from clinical practice, research, and teaching. Their scientific work aims at the responsible and at the same time rapid introduction of new therapies that save lives and maintain quality of life. Their university clinic offers the medical offspring limitless opportunities to expand their knowledge. It is founded in 1457 in Freiburg, Germany.

Incyte is a drug discovery and development company which hopes to build a proprietary product pipeline of novel small molecule drugs. Incyte's product pipeline is currently focused on oncology and inflammation and includes compounds in various stages of development. Through partnerships with [Novartis](/organization/novartis), [Eli Lilly](/organization/eli-lilly), and [Pfizer](/organization/pfizer), Incyte intends to promote the clinical development and global commercialization of several of their compounds.

Takeda Pharmaceutical Company Ltd (武田薬品工業株式会社 Takeda Yakuhin Kōgyō Kabushiki-gaisha) is the largest pharmaceutical company in Asia and one of the top 20 largest pharmaceutical companies in the world by revenue (top 10 following merger with Shire). The company has over 30,000 employees worldwide and achieved 16.2 billion USD in revenue during the 2012 fiscal year. The company is focused on metabolic disorders, gastroenterology, neurology, inflammation, as well as oncology through its independent subsidiary, Takeda Oncology. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo. In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States.

Quanticel Pharmaceuticals is a privately held drug discovery company committed to the development of breakthrough medicines for the treatment of cancer. Quanticel's proprietary platform for single-cell genomic analysis of human cancer is designed to enable the discovery of first-in-class oncology therapeutics.

Established in 1973 in Korea, Hanmi Pharmaceuticals now is one of the top 5 pharmaceutical companies in terms of revenue, and the most R&D focused company with the highest R&D investment for several years. Hanmi has been successful for a few decades with high flexibility, continuously changing its market/development strategy from first generics to IMD & FDC (Incrementally Modified Drug and Fixed Dose Combination) to new drug development including innovative small molecules and biologics. During the period of significant changes, Hanmi made multiple strategic collaboration relationships with multinational companies and biotech companies. Based on the success in 1980s and 1990s, Hanmi started its Chinese operation in 1996 with establishment of Beijing Hanmi. Now, Beijing Hanmi grew as a well-localized and well-settled Chinese company with more than 1,300 staffs including R&D, sales / marketing, and manufacturing experts and significant growth rate higher than 20% every year. Currently, Hanmi and Beijing Hanmi is closely collaborating on various business opportunities and new drug development projects as well as sales and marketing in Chinese territories. As the only Asian company with significant presence both in Korea and China, as the most R&D focused company with number of clinical stage projects with competitiveness, and as the company with open innovation based on multiple development/marketing collaborations, Hanmi is trying to develop and provide differentiated treatment options to patients suffering from various disease.

Celgene Corporation is an American biotechnology company that discovers, develops and commercializes medicines for cancer and inflammatory disorders. It is incorporated in Delaware and headquartered in Summit, New Jersey. The company's major product is Revlimid (lenalidomide), in combination with dexamethasone for the treatment of multiple myeloma patients. Revlimid is also approved in the United States for the treatment of patients with transfusion-dependent anemia, due to Low- or Intermediate-1-risk Myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. Revlimid is sold through proprietary risk-management distribution programs, to ensure safe and appropriate use of these pharmaceuticals. Vidaza is approved for the treatment of patients with MDS.

EpiAxis Therapeutics is pursuing a preclinical and clinical drug development program directed at the prevention of metastatic disease by targeting the pivotal enzyme system controlling the proliferation of cancer stem cells (CSC). Specifically, that target is the nuclear bound lysine-specific demethylase 1 (LSD1) & its upstream regulator, the theta isoform of protein kinase C (PKC theta). The research identifying this target and the intellectual property (IP) that resulted from this was developed by Professor Sudha Rao and colleagues at the University of Canberra (UC), Australia. The Company is focused initially on the prevention of metastatic breast cancer, with other CSC mediated diseases such as ovarian, pancreatic, colon, melanoma, lung and liver cancers to be pursued later. EpiAxis is positioning itself to become the leading cancer recurrence prevention company with its proprietary LSD1 & PKC theta inhibitors included in the standard of care (SoC) for cancer.

Chugai Pharmaceutical Co., Ltd. engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals. Its operations are carried out through the Domestic and Overseas businesses. The Domestic Business covers the manufacturing, research, and development operations in Japan. The Overseas business comprises of sales and production in Europe, Taiwan and China. The company was founded by Juzo Ueno on March 10, 1925 and is headquartered in Tokyo, Japan.

Manufactures, marketes and imports, exports pharmaceutical drugs

Part of CSPC Pharmaceutical Group Ltd., CSPC Zhongqi Pharmaceutical Technology Shijiazhuang Co., Ltd. is a company headquartered in China. The firm engages in pharmaceutical research and development.

Fujian Jinle Pharmaceutical Technology Co., Ltd., established on 2014-06-27, Business scope includes drug development;Pharmaceutical market consultant;Medical technology research and development;Goods import and export business.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Shanghai Dino Medical Technology Co., Ltd. is a science-driven innovative biotechnology company dedicated to the research and development of clinically unsatisfied drugs in the field of cancer. Founded in 2010, the company is located in Zhangjiang Hi-Tech Park, Pudong New Area, Shanghai.

Shenzhen True Biomedical Technology Co., Ltd., established on 2020-01-02, Business scope includes general business items:,The licensing program is:research and development,Manufacture and sales of anticancer drugs,antiviral drugs,Drugs for treating diabetes-related diseases and drugs for cardiovascular and cerebrovascular diseases and aging-related diseases;Medical Raw Materials,medical tablet,soft,hard capsule,Granules,Powder,Research and Development of Biologics,production and sales;Research and development of biomedical technology,Consulting and Services;R&D of general chemical products,production and sales;Research and development of biopharmaceutical products,production and sales(Except for the goods and technologies that the state restricts the company to operate or prohibits the import and export of)(law,Administrative regulations,Except for items prohibited by the State Council,Restricted projects must obtain a license before operating)

Riken Corp. engages in the manufacture and sale of engine and vehicular components. It operates through the Automotive and Machinery Parts, and Others segments. The Automotive and Machinery Parts segment deals with the company's core products such as piston rings, camshafts, seal rings for transmissions, high-grade cast iron products, and valve lifters. The Others segment includes plumbing equipment business, Electromagnetic Compatibility (EMC) business, and thermal engineering business, The company was founded by Masatoshi Okochi in November 1927 and is headquartered in Tokyo, Japan.

GlaxoSmithKline Intellectual Property (No. 2) Ltd., a subsidiary of GSK Plc, is a company headquartered in Brentford, UK, that provides business support services. The firm was founded in 2012.\nThe company says this about itself: The Company is a member of the GlaxoSmithKline Group (the \"Group\"). The Company's principal activities are the development, enhancement, maintenance, protection and exploitation of intellectual property assets owned by the Company which may include but are not limited to, licensing out intellectual property rights relating to pharmaceutical products to the GlaxoSmithKline Group of companies and carrying out research and development activities.

Jichi Medical University (自治医科大学 Jichi ika daigaku) is a private university in Shimotsuke, Tochigi, Japan, established in 1972. In 2008 the Gates Foundation awarded $100,000 to Hiroyuki Matsuoka, a medical researcher at the university, to do research on flying syringes.

Nanjing Mingde New Drug Research and Development Co., Ltd., established on 2011-12-16, The scope of business includes engaging in pharmaceutical,Biological product,medical instruments,food development,Research;Environmental and pesticide testing services;Pharmaceutical Small Molecule Compound Library,Preclinical studies of drug leads and drug products,Technology development related to process development and clinical research,Technology introduction,Technical Services,Technical consulting and technology transfer,related technology,Licensing of Patents and Intellectual Property,Achievement Transformation and Transfer;Self-operated and agent import and export business of various commodities and technologies(Except for commodities and technologies that the state restricts enterprises to operate or prohibits import and export).(Items subject to approval by law,Business activities can only be carried out after approval)

Nanchang Hongyi Technology Co., Ltd., established on 1998-01-04, Business scope includes pharmaceutical,Health products,Technology development in food chemical industry,technology transfer,technical consulting,Technical Services(The operating permit) **